SI2001456T1 - Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni - Google Patents

Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni

Info

Publication number
SI2001456T1
SI2001456T1 SI200730163T SI200730163T SI2001456T1 SI 2001456 T1 SI2001456 T1 SI 2001456T1 SI 200730163 T SI200730163 T SI 200730163T SI 200730163 T SI200730163 T SI 200730163T SI 2001456 T1 SI2001456 T1 SI 2001456T1
Authority
SI
Slovenia
Prior art keywords
treatment
opioid receptor
receptor antagonist
kappa opioid
containing compositions
Prior art date
Application number
SI200730163T
Other languages
English (en)
Inventor
Lars-Holger Dr Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of SI2001456T1 publication Critical patent/SI2001456T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200730163T 2006-04-04 2007-04-03 Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni SI2001456T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
EP07727719A EP2001456B1 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
SI2001456T1 true SI2001456T1 (sl) 2010-04-30

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730163T SI2001456T1 (sl) 2006-04-04 2007-04-03 Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni

Country Status (17)

Country Link
US (1) US8063059B2 (sl)
EP (1) EP2001456B1 (sl)
JP (1) JP5128578B2 (sl)
AT (1) ATE450256T1 (sl)
AU (1) AU2007236003B2 (sl)
CA (1) CA2646899C (sl)
CY (1) CY1109862T1 (sl)
DE (1) DE502007002185D1 (sl)
DK (1) DK2001456T3 (sl)
EA (1) EA014820B1 (sl)
ES (1) ES2337622T3 (sl)
HR (1) HRP20100113T1 (sl)
PL (1) PL2001456T3 (sl)
PT (1) PT2001456E (sl)
RS (1) RS51211B (sl)
SI (1) SI2001456T1 (sl)
WO (1) WO2007115975A2 (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2252581T3 (da) 2008-01-22 2012-07-16 Lilly Co Eli Kappa-selektiv opioidreceptorantagonist
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10376506B2 (en) * 2013-12-20 2019-08-13 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
SG11201608918SA (en) 2014-04-28 2016-11-29 Orphomed Inc Pharmaceutically active dimers linked through phenolic hydroxyl groups
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
WO1999045906A1 (en) * 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
WO2002013759A2 (en) 2000-08-15 2002-02-21 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
AU2004227833B2 (en) * 2003-04-04 2009-10-01 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
CA2556380A1 (en) * 2004-03-02 2005-09-15 Pharmacia Corporation Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
WO2005117838A1 (en) * 2004-06-02 2005-12-15 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and derivatives

Also Published As

Publication number Publication date
CA2646899A1 (en) 2007-10-18
PL2001456T3 (pl) 2010-05-31
DE502007002185D1 (de) 2010-01-14
EA014820B1 (ru) 2011-02-28
CY1109862T1 (el) 2014-09-10
ATE450256T1 (de) 2009-12-15
US20090181999A1 (en) 2009-07-16
PT2001456E (pt) 2010-03-03
ES2337622T3 (es) 2010-04-27
JP5128578B2 (ja) 2013-01-23
EP2001456B1 (de) 2009-12-02
AU2007236003B2 (en) 2012-10-18
DK2001456T3 (da) 2010-04-12
AU2007236003A1 (en) 2007-10-18
EA200802104A1 (ru) 2009-04-28
WO2007115975A2 (de) 2007-10-18
WO2007115975A3 (de) 2008-02-14
RS51211B (sr) 2010-12-31
EP2001456A2 (de) 2008-12-17
JP2009532434A (ja) 2009-09-10
US8063059B2 (en) 2011-11-22
HRP20100113T1 (hr) 2010-04-30
CA2646899C (en) 2014-05-06

Similar Documents

Publication Publication Date Title
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
SI1729753T1 (sl) Uporaba antagonistov NMDA receptorjev za zdravljenje tinitusa povzročenega s kohlearno eksitotoksičnostjo
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
NZ594140A (en) C5ar antagonists
EP2215049A4 (en) P2X3 RECEPTOR ANTAGONISTS USED IN THE TREATMENT OF PAIN
HK1134084A1 (en) Pyridyl piperidine orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
HK1120442A1 (en) Novel opioid antagonists
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
PT2001876E (pt) Compostos de 8-azabiciclo[3.2.1]octano como antagonistas do receptor opióide mu
RS20090208A (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
PL2238110T3 (pl) Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
HK1094674A1 (en) Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases cb1
SI2001456T1 (sl) Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
ZA200900613B (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders
HK1102303A1 (en) Synthesis of ccr5 receptor antagonists ccr5
MX2009006313A (es) Antagonistas v3 para el tratamiento o prevencion de dolor cronico.